Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 
Press Release
 View printer-friendly version << Back

Agios Pharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference

Cambridge, Mass. - January 6, 2011 - Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that David Schenkein, M.D., chief executive officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2011 at 11:00 AM PST at the Westin St. Francis Hotel in San Francisco.

Dr. Schenkein is expected to discuss the potential of cancer metabolism, one of the most promising new areas of medicine, as well as the assets and capabilities that position Agios as a leader in this field.

About Agios Pharmaceuticals
Agios Pharmaceuticals is the first biopharmaceutical company dedicated to the discovery and development of novel therapeutics in the emerging field of cancer metabolism. To support and drive these efforts, Agios is building a robust platform integrating metabolomics, genetics, biochemistry and microscopy to enable biomarker and target identification. Agios’ platform of differential cellular metabolism of diseased cells relative to normal cells will also be applicable to other therapeutics areas including autoimmune, inflammatory and neurological diseases. The Company’s founders represent the core thought leaders in the field of cancer metabolism, responsible for key advances, insights and discoveries in the field. Agios Pharmaceuticals is located in Cambridge, Massachusetts.  For more information, please visit the company's website at

Media Contact:
Dan Budwick
Pure Communications
(973) 271-6085